Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

HIV is surging among adults over 50 in sub-Saharan Africa, yet prevention and treatment campaigns still focus mainly on the ...

Some staffers at the U.S. Agency for International Development describe racing the clock to try to push out promised funds ...

Steep funding cuts to the United States Agency for International Development (USAID) could result in over 1.4 crore ...

The FDA approved Yeztugo (lenacapavir), a twice-yearly injection that prevents HIV with up to 99.9% effectiveness, showing zero infections in women and nearly perfect protection in men.

Use in areas like sub-Saharan Africa is low, but is likely to be cost-effective and even cost-saving if delivered at scale, according to a study published in The Lancet HIV journal last year.

On May 10, 2025, UNAIDS announced that it planned to cut its staff by 54%. The number of countries where the organisation maintains a physical presence will also drop, from 85 to nearer 30. Some of ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

A 15-year retrospective study from southeastern Romania has revealed a high mortality burden associated with HIV-related ...

The Lancet Oncology was launched in September, 2000, as a lively and informative monthly journal covering international issues relevant to clinical cancer specialists worldwide. The journal is now ...

Human immunodeficiency virus (HIV) is a germ that causes a lifelong infection that slowly weakens the immune system. Though the infection is lifelong, medicines can keep the virus in check and ...